FWP
TRAW icon

FAS Wealth Partners’s Traws Pharma TRAW Stock Holding History

FAS Wealth Partners’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-101
Closed -$38K – 381
2021
Q1 		$38K Hold
101
– – ﹤0.01% 303
2020
Q4 		$18K Buy
+101
New +$11.7K ﹤0.01% 312

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

FAS Wealth Partners's TRAW Position: Q2 2021 in Review

FAS Wealth Partners sold out of Traws Pharma (TRAW) in Q2 2021, closing a stake of 101 shares — an estimated $38K sold.

FAS Wealth Partners first reported a position in TRAW in Q4 2020 and held it in 2 quarters. The position peaked at $38K in Q1 2021. 25 funds tracked by Wall St. Rank hold TRAW as of Q2 2021.

  • FAS Wealth Partners reported no remaining Traws Pharma position as of Q2 2021 after selling out during the quarter.
  • FAS Wealth Partners sold 101 Traws Pharma shares in Q2 2021, an estimated $38K.
  • FAS Wealth Partners first reported a position in Traws Pharma in Q4 2020 and held it in 2 quarters.
  • FAS Wealth Partners's Traws Pharma position peaked at $38K in Q1 2021.
  • 25 funds tracked by Wall St. Rank held Traws Pharma as of Q2 2021.

Based on FAS Wealth Partners's 13F filing for Q2 2021, filed 29 Jul 2021.